SCHEDULE: Vivo Funds Disclose 3.4% Stake in COMPASS Pathways

Vivo Opportunity Fund Holdings and affiliates reported a combined 3.4% beneficial ownership in COMPASS Pathways plc, primarily through warrants.

Summary

• Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, beneficially own 3,174,494 Ordinary Shares of COMPASS Pathways plc, represented by American Depositary Shares (ADSs).
• This ownership represents 3.2% of the Issuer's outstanding Ordinary Shares.
• Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, beneficially own an additional 187,891 Ordinary Shares, also represented by ADSs.
• This additional ownership represents 0.2% of the Issuer's outstanding Ordinary Shares.
• The total combined beneficial ownership by Vivo entities is 3,362,385 shares, representing approximately 3.4% of the class.
• All reported securities are issuable upon the exercise of certain warrants, which are subject to a beneficial ownership limitation of 9.99% of the Issuer's outstanding Ordinary Shares.
• The percentage of class is calculated based on 96,017,044 Ordinary Shares outstanding as of October 30, 2025, as reported in the Issuer's Form 10-Q filed on November 4, 2025, plus the shares issuable upon warrant exercise.
• The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by institutional investors like Vivo Funds, even if through warrants, generally indicates a positive sentiment and confidence in the company's future prospects. It suggests that sophisticated investors see value in COMPASS Pathways plc.

Positives

• A significant beneficial ownership stake by institutional investors like Vivo Funds can signal confidence in COMPASS Pathways plc's long-term prospects.
• The investment is primarily through warrants, indicating a potential future commitment to convert to equity.

Negatives

• No specific negatives are detailed in this beneficial ownership report.

Risks

• The beneficial ownership is subject to a 9.99% limitation upon exercise of warrants, which could cap the immediate influence of the reporting persons.
• The value of the warrants and the underlying shares is subject to market fluctuations and the future performance of COMPASS Pathways plc.

Future Outlook

NA

Industry Context

The filing indicates continued institutional investor interest in the biotechnology and mental health treatment sector, where COMPASS Pathways plc operates, focusing on psilocybin therapy.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a stake can be viewed positively, potentially boosting investor confidence and signaling long-term interest in the company.
• Company Management: The presence of a significant investor may lead to increased scrutiny or engagement, though the filing explicitly states the securities were not acquired for changing or influencing control.

Key Dates

Recommendation

This Schedule 13G filing primarily reports a beneficial ownership stake by Vivo Funds. While the significant stake (3.4%) by institutional investors can be seen as a positive signal of confidence in COMPASS Pathways plc, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. The investment is through warrants, indicating a future potential conversion. Investors should 'hold' and monitor future company performance and further disclosures for a more comprehensive investment decision.

Keywords

COMPASS Pathways plc, CMPS, Vivo Opportunity Fund Holdings, Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, Vivo Opportunity Cayman, LLC, Schedule 13G, beneficial ownership, warrants, American Depositary Shares, ADSs, biotechnology, pharmaceuticals, investment fund, institutional ownership